Trial Profile
An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms Afatinib PEGx study
- 30 Jan 2022 According to UMIN, last follow up date changed from 31 Mar 2019 to 14 Jan 2023.
- 26 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2018 New trial record